Hua Mei Lin

US Patent:

20220185797, Jun 16, 2022

Filed:

Mar 25, 2020

Appl. No.:

17/598695

Inventors:

- New York NY, US
- Weston MA, US
Donald W. LANDRY - New York NY, US
Robert J. DEVITA - Westfield NJ, US
Hua V. LIN - Zionsville IN, US
Yunkyoung LEE - New York NY, US
Domenico ACCILI - New York NY, US
Sandro BELVEDERE - Weston MA, US

International Classification:

C07D 403/04
A61K 31/713
A61K 31/4184
A61K 31/496
C07D 401/14
A61K 31/454
C07D 405/14
C07D 413/14
A61K 31/423
A61K 31/4709
A61K 31/4439
C07D 471/04
A61K 31/437

Abstract:

Various embodiments relate to a compound (represented by Formula I) or a pharmaceutically acceptable salt or tautomer thereof. The compound may selectively inhibit a Forkhead Box O1 (FOXO1) transcription factor. Various embodiments relate to methods comprising administering to a mammal having a disease or disorder associated with impaired pancreatic endocrine function, a therapeutically effective amount of the compound or a pharmaceutically acceptable salt or tautomer thereof. Various embodiments relate to methods for producing enteroendocrine cells that make and secrete insulin in a mammal, comprising administering to the mammal an effective amount of the compound or a pharmaceutically acceptable salt or tautomer thereof.